Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.48 |
| ▸ | ABL1 | P00519 | 14/20 | 0.43 |
| ▸ | HCK | P08631 | 12/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.40 |
| ▸ | PRKDC | P78527 | 12/20 | 0.40 |
| ▸ | KDR | P35968 | 11/20 | 0.40 |
| ▸ | MTOR | P42345 | 11/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 11/20 | 0.40 |
| ▸ | EGFR | P00533 | 10/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.40 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.38 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20093481 | 0.87 | KMO (0.46) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL13717800 | 0.87 | CSNK1E (0.45) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL20093561 | 0.81 | BTK (0.47) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL21364711 | 0.80 | MAP4K4 (0.52) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL149180 | 0.79 | PIK3CD (0.55) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL21772444 | 0.78 | MAPK1 (0.42) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL13828353 | 0.77 | SRC (0.63) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL22854507 | 0.76 | SRC (0.35) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL13717774 | 0.76 | PIK3CD (0.41) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL22275989 | 0.76 | MAP4K4 (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478481-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS AG (CH) | 2022-10-25 | — | — | US | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| EP-2844647-B1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS S A (CH) | 2020-07-22 | — | — | EP | disclosed |
| EP-2844647-B1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS S A (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-06-18 | — | — | US | disclosed |
| US-20150087699-A1 | NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| EP-2844647-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | Rhizen Pharmaceuticals S.A. (CH) | 2015-03-11 | — | — | EP | disclosed |
| EP-2705029-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | Rhizen Pharmaceuticals S.A. (CH) | 2014-03-12 | — | — | EP | disclosed |
| WO-2013164801-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS SA (CH) | 2013-11-07 | — | — | WO | disclosed |
| WO-2012151525-A9 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012151525-A9 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| WO-2012151525-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151525-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SRC 285/4885ABL1 334/4885HCK 612/4885 |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | SRC 85/4885ABL1 106/4885HCK 340/4885 |
| US-20150087699-A1 | NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | CYP4B1, ADH1A, CYP1A2 | SRC 3541/4885ABL1 2058/4885HCK 1791/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SRC 285/4885ABL1 334/4885HCK 612/4885 |
| US-11478481-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | CYP4B1, ADH1A, CYP1A2 | SRC 3736/4885ABL1 1564/4885HCK 1570/4885 |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SRC 285/4885ABL1 334/4885HCK 612/4885 |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | MAP3K1, CSNK1A1, MAP3K2 | SRC 90/4885ABL1 376/4885HCK 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.